Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

Completed · Phase 3

Conditions studied: Major Depression Disorder

In brief

The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment

Key facts

Study ID

NCT02400346

Run by

H. Lundbeck A/S

People needed

132

Starts

2015-03-01

Expected to finish

2016-06-01

Last updated by the study team

2017-08-10

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• US012 — Arcadia, California, United States
• US004 — Miami, Florida, United States
• US007 — Orlando, Florida, United States
• US006 — Smyrna, Georgia, United States
• US002 — O'Fallon, Missouri, United States
• US010 — Toms River, New Jersey, United States
• US005 — New York, New York, United States
• US008 — New York, New York, United States
• US003 — Staten Island, New York, United States
• US014 — Oklahoma City, Oklahoma, United States
• US009 — Allentown, Pennsylvania, United States
• US001 — Memphis, Tennessee, United States
• US011 — San Antonio, Texas, United States
• EE002 — Tallinn, Estonia
• EE001 — Tartu, Estonia
• EE004 — Tartu, Estonia
• EE003 — Võru, Estonia
• FI001 — Helsinki, Finland
• FI002 — Kuopio, Finland
• FI003 — Oulu, Finland
• FI004 — Tampere, Finland
• DE002 — Berlin, Germany
• DE008 — Berlin, Germany
• DE003 — Frankfurt, Germany
• DE007 — Hanover, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.